Patient-provider communication about medication cost in rheumatoid arthritis.
K Julia KaalNick BansbackMarie HudsonAslam AnisCheryl KoehnMark HarrisonPublished in: Clinical rheumatology (2020)
Discussions about cost do not always happen, even with diseases with potentially high medication costs like RA. Cost was more likely to be discussed by patients who perceived it as "very important," suggesting the onus might be on patients to initiate these conversations. Without any significant predictors regarding what may make physicians more likely to think it was important to discuss medication costs, there is a need to reinforce recommendations that all physicians seek to discuss costs with all of their patients when suggesting medications. Key Points • There is a need for patients and physicians to discuss costs in the treatment decision-making process. Our findings suggest this does not always happen. • Among patients, medication cost was more likely to be discussed by those who perceived it as "very important" and higher perceived importance of discussing out-of-pocket costs was associated with a more positive attitude to shared decision-making. • Our results did not reveal any significant predictors regarding what may make physicians more likely to think it was important to discuss medication costs, suggesting that there is a need to reinforce recommendations that all physicians seek to discuss medication costs with all of their patients when suggesting medications.
Keyphrases
- end stage renal disease
- primary care
- rheumatoid arthritis
- ejection fraction
- healthcare
- chronic kidney disease
- newly diagnosed
- prognostic factors
- physical activity
- depressive symptoms
- mental health
- emergency department
- decision making
- adverse drug
- gene expression
- systemic lupus erythematosus
- case report
- single cell
- electronic health record